All neuroblastoma cell lines with wildtype TP53 responded to DS-3032b treatment, regardless of the presence of MYCN amplifications, indicating that this MDM2 inhibitor may benefit high-risk patients with neuroblastomas having several molecular backgrounds. This evidence concerns the gene MDM2 and neuroblastoma.